Angiotensin II and Hypertension

Cardiovascular Peptides

8 amino acids

Angiotensin II is one of the most pharmacologically targeted peptides in medicine, with ACE inhibitors and ARBs prescribed to over 1 billion patients worldwide.

Ahmad et al., Biochemistry and Pharmacology, 2023

Ahmad et al., Biochemistry and Pharmacology, 2023

View as image

Angiotensin II (Ang II) is an eight-amino-acid peptide (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) that sits at the center of blood pressure regulation. It is the primary effector of the renin-angiotensin-aldosterone system (RAAS), the hormonal cascade that the body uses to maintain blood pressure when blood volume drops, sodium is low, or renal perfusion falls. Two of the most prescribed drug classes in cardiovascular medicine, ACE inhibitors and angiotensin receptor blockers (ARBs), exist solely to reduce Ang II's activity. For a broader view of how cardiovascular peptides work together, see our pillar article on Adrenomedullin: The Blood Vessel Relaxing Peptide. For the peptide that directly opposes angiotensin II's effects on blood pressure, see ANP: The Atrial Peptide That Lowers Blood Pressure.

The RAAS Cascade: From Renin to Angiotensin II

The formation of angiotensin II follows a three-step enzymatic cascade. When renal perfusion pressure drops, sympathetic nervous system activity increases, or sodium delivery to the macula densa decreases, juxtaglomerular cells in the kidney release renin into the bloodstream. Renin is an aspartyl protease that cleaves angiotensinogen (a 452-amino-acid protein constitutively produced by the liver) into the decapeptide angiotensin I (Ang I).

Angiotensin I has minimal biological activity. Its conversion to the active octapeptide angiotensin II requires angiotensin-converting enzyme (ACE), a zinc metallopeptidase expressed on the surface of endothelial cells, with particularly high concentrations in the pulmonary vasculature. ACE removes the C-terminal dipeptide His-Leu from Ang I, producing the active Asp-Arg-Val-Tyr-Ile-His-Pro-Phe sequence of Ang II.^[1]

ACE is not specific to the RAAS. It also degrades bradykinin, a vasodilatory peptide, and substance P. This dual function means that ACE inhibition simultaneously reduces a vasoconstrictor (Ang II) and preserves a vasodilator (bradykinin), producing a net blood pressure effect larger than either mechanism alone.

This is why the lungs are the primary site of Ang II generation: venous blood passes through the pulmonary capillary bed where ACE is densely expressed, and Ang II enters the arterial circulation ready to act on its target tissues. For a detailed examination of how blocking this enzyme lowers blood pressure, see ACE Inhibitors: How Blocking a Peptide Enzyme Lowers Blood Pressure.

How Angiotensin II Raises Blood Pressure

Ang II raises blood pressure through three parallel mechanisms, each mediated by the angiotensin type 1 (AT1) receptor.

Direct Vasoconstriction

Ang II is one of the most potent vasoconstrictors produced by the body. Binding to AT1 receptors on vascular smooth muscle cells activates phospholipase C, increases intracellular calcium, and triggers contraction. The effect is rapid (seconds to minutes) and predominantly affects arteriolar resistance vessels, directly increasing systemic vascular resistance and arterial blood pressure.

Aldosterone Release

Ang II stimulates the adrenal cortex (zona glomerulosa) to secrete aldosterone, a mineralocorticoid that acts on the distal nephron to increase sodium reabsorption and potassium excretion. Sodium retention obligates water retention, expanding plasma volume and increasing blood pressure. This effect operates over hours to days and sustains blood pressure elevation beyond the acute vasoconstrictive response.

Sympathetic Activation and Renal Effects

Ang II enhances sympathetic nervous system outflow at multiple levels: it stimulates norepinephrine release from sympathetic nerve terminals, inhibits norepinephrine reuptake, and acts centrally to increase sympathetic tone. In the kidney, Ang II constricts the efferent arteriole more than the afferent, maintaining glomerular filtration pressure while reducing renal blood flow and promoting sodium reabsorption in the proximal tubule.

AT1 vs AT2: Two Receptors, Opposing Effects

Angiotensin II acts through two principal receptor subtypes with opposing cardiovascular effects.

The AT1 receptor mediates vasoconstriction, aldosterone secretion, sodium retention, cardiac hypertrophy, vascular remodeling, fibrosis, inflammation, and oxidative stress. Virtually all of Ang II's pathological effects in hypertension and cardiovascular disease signal through AT1.

The AT2 receptor, discovered later and less well characterized, mediates vasodilation, anti-proliferation, anti-inflammatory effects, and promotion of apoptosis in cardiovascular cells. AT2 activation by Ang II opposes AT1-mediated effects, suggesting an endogenous counterbalancing mechanism. AT2 is highly expressed in fetal tissues and declines in adulthood, with re-expression occurring during tissue injury and remodeling.

ARBs like valsartan and losartan selectively block AT1 receptors, leaving Ang II free to stimulate AT2, potentially contributing to their cardiovascular protective effects beyond blood pressure lowering. Tsutamoto and colleagues demonstrated that the ARB valsartan reduced plasma TNF-alpha, IL-6, and soluble adhesion molecules in chronic heart failure patients, showing that AT1 blockade has anti-inflammatory effects that extend beyond hemodynamics.^[2]

The dual-receptor system creates a built-in regulatory tension. In healthy individuals, AT1 and AT2 signaling remain balanced. In pathological states (chronic hypertension, heart failure, diabetic nephropathy), AT1 expression increases while AT2 expression remains stable or decreases, tilting the balance toward vasoconstriction, inflammation, and fibrosis. This receptor imbalance is one reason why simple blood pressure normalization with non-RAAS drugs does not provide the same organ-protective benefits as ACE inhibitors or ARBs: blocking AT1 specifically, rather than just lowering pressure, restores the AT1/AT2 balance and unmasks AT2-mediated protective effects.

ACE2 and the Counter-Regulatory Arm

In 2000, Donoghue and colleagues identified a novel homolog of ACE, called ACE2, that converts Ang II into angiotensin (1-7), a heptapeptide with vasodilatory, anti-inflammatory, and anti-fibrotic properties.^[3] Wang and colleagues later confirmed that ACE2 metabolizes Ang II with high catalytic efficiency, establishing it as the primary enzymatic pathway for Ang II degradation.^[4]

The ACE2/Ang (1-7)/Mas receptor axis functions as a counter-regulatory arm of the RAAS. Where ACE generates the vasoconstrictor Ang II, ACE2 degrades it into the vasodilator Ang (1-7). The balance between these two enzymatic pathways determines the net cardiovascular effect of RAAS activation. In hypertension and heart failure, ACE activity is upregulated while ACE2 is downregulated, shifting the balance toward vasoconstriction and tissue damage.

ACE2 gained global prominence as the cellular entry receptor for SARS-CoV-2. The virus's spike protein binds ACE2 on respiratory epithelial cells to enter cells, simultaneously reducing ACE2 surface expression and shifting the local ACE/ACE2 balance toward Ang II excess. This mechanism may explain the cardiovascular complications observed in severe COVID-19.

Angiotensin II Beyond Blood Pressure

Ang II's effects extend far beyond hemodynamics. Through AT1 receptors, it drives cardiac hypertrophy, vascular remodeling, renal fibrosis, and systemic inflammation.

Cardiac Remodeling

Chronic Ang II stimulation promotes cardiac myocyte hypertrophy and fibroblast proliferation, leading to pathological cardiac remodeling. This is why ACE inhibitors and ARBs reduce heart failure mortality: they block Ang II-driven remodeling independent of blood pressure effects.

Cognitive Effects

Ang II has direct central nervous system effects that influence cognitive function. Ho and colleagues (2018) reviewed evidence that angiotensin receptor blockade provides cognitive benefits beyond blood pressure lowering, potentially through reduced neuroinflammation, improved cerebrovascular function, and modulation of brain RAAS signaling.^[5]

Cancer Risk

Sipahi and colleagues (2010) conducted a meta-analysis examining whether ARB use was associated with cancer risk. The analysis found a modestly increased risk of new cancer diagnoses with ARBs, though subsequent larger meta-analyses and regulatory reviews concluded the association was not causal. The episode highlights that blocking a peptide signaling system can have effects that extend well beyond the intended target tissue.^[6]

Therapeutic Targeting of the RAAS

Three drug classes target the RAAS at different points.

ACE inhibitors (captopril, enalapril, lisinopril) block the conversion of Ang I to Ang II. They also prevent ACE from degrading bradykinin, a vasodilatory peptide, which contributes to their blood pressure-lowering effect but also causes the characteristic dry cough in 5-20% of patients. For more on how bradykinin accumulation explains this side effect, see Bradykinin: The Peptide Behind ACE Inhibitor Cough.

ARBs (losartan, valsartan, candesartan) selectively block the AT1 receptor, preventing Ang II from exerting its vasoconstrictor and pro-inflammatory effects while leaving AT2 signaling intact. They do not affect bradykinin metabolism, which is why they cause less cough than ACE inhibitors.

Sacubitril/valsartan (Entresto) combines an ARB with a neprilysin inhibitor. Neprilysin degrades natriuretic peptides (ANP, BNP); blocking it raises natriuretic peptide levels, producing vasodilation, natriuresis, and anti-remodeling effects. This drug represents the convergence of two peptide systems: reducing Ang II's harmful effects while boosting natriuretic peptides' protective effects.^[7] For a detailed analysis of this combination approach, see Sacubitril/Valsartan: The Drug That Boosts Natriuretic Peptides.

Food-Derived ACE Inhibitory Peptides

Enzymatic hydrolysis of food proteins generates peptides that inhibit ACE in vitro, and some have demonstrated blood pressure-lowering effects in clinical trials. The tripeptides IPP (Ile-Pro-Pro) and VPP (Val-Pro-Pro) from fermented milk are the best-studied examples. Saito (2008) reviewed the evidence for casein- and whey-derived ACE inhibitory peptides, documenting multiple peptide sequences with demonstrated ACE inhibition and, in some cases, clinical blood pressure reduction.^[8]

Da and colleagues (2022) reviewed the broader landscape of peptide-based ACE inhibitors, including synthetic and food-derived peptides, noting the structural features that determine ACE inhibitory potency: hydrophobic residues at the C-terminus, the presence of proline, and specific chain lengths (2-12 amino acids) that fit the ACE active site.^[9] For a dedicated analysis of food-derived ACE inhibitors, see ACE-Inhibitory Peptides in Food: Natural Blood Pressure Management.

The Broader Peptide Context

Angiotensin II does not operate in isolation. It interacts with multiple peptide systems: natriuretic peptides oppose its effects on sodium handling, endothelin amplifies vasoconstriction through separate receptors, apelin acts as a counter-regulatory vasodilator, and bradykinin mediates some of the therapeutic benefit of ACE inhibition. The vasopeptidase inhibitor concept, simultaneously blocking ACE and neprilysin, reflects the recognition that cardiovascular homeostasis depends on the balance among multiple peptide systems rather than any single pathway.^[10]

The limitations of the current evidence are primarily in the food-derived peptide space, where in vitro ACE inhibition does not reliably predict in vivo blood pressure effects due to peptide degradation during digestion and limited oral bioavailability. For pharmaceutical ACE inhibitors and ARBs, the evidence base is exceptionally strong, built on decades of randomized controlled trials involving millions of patients.

The Bottom Line

Angiotensin II is an eight-amino-acid peptide that drives hypertension through vasoconstriction, aldosterone-mediated sodium retention, and sympathetic activation, all via AT1 receptors. The discovery of ACE2 revealed a counter-regulatory pathway that converts Ang II into the vasodilatory angiotensin (1-7). Two of the most prescribed drug classes in medicine (ACE inhibitors and ARBs) target this peptide, and the combination of ARBs with neprilysin inhibitors represents the therapeutic convergence of the angiotensin and natriuretic peptide systems. Ang II's effects extend beyond blood pressure to cardiac remodeling, inflammation, and potentially cognition, making it one of the most clinically consequential peptides in human biology.

Frequently Asked Questions

What does angiotensin II do to blood pressure?

Angiotensin II raises blood pressure through three parallel mechanisms: direct vasoconstriction of arteriolar smooth muscle (increasing vascular resistance within seconds), stimulation of aldosterone release from the adrenal cortex (causing sodium and water retention over hours), and enhancement of sympathetic nervous system activity. All three effects are mediated by the AT1 receptor.

How is angiotensin II formed in the body?

Angiotensin II is formed by a two-step enzymatic cascade. First, renin (released by the kidneys when blood pressure drops) cleaves the liver protein angiotensinogen into the decapeptide angiotensin I. Then angiotensin-converting enzyme (ACE), concentrated in the lung vasculature, removes two amino acids from angiotensin I to produce the active octapeptide angiotensin II.

What is the difference between ACE inhibitors and ARBs?

ACE inhibitors (like lisinopril) block the enzyme that converts angiotensin I to angiotensin II, reducing Ang II production. ARBs (like losartan) block the AT1 receptor that Ang II activates, preventing its effects even when Ang II is present. ACE inhibitors also prevent bradykinin degradation, which causes cough in 5-20% of patients. ARBs do not affect bradykinin and cause less cough (Tsutamoto et al., 2000).

What is ACE2 and how does it relate to angiotensin II?

ACE2 is an enzyme discovered in 2000 that converts the vasoconstrictor angiotensin II into the vasodilator angiotensin (1-7). It acts as a counter-regulatory mechanism within the RAAS. ACE2 also serves as the cellular entry receptor for SARS-CoV-2, and viral binding reduces ACE2 surface expression, potentially shifting the local balance toward harmful Ang II excess (Donoghue et al., 2000; Wang et al., 2016).

Can food peptides lower blood pressure like ACE inhibitors?

Some food-derived peptides inhibit ACE in laboratory assays, and the tripeptides IPP and VPP from fermented milk have shown modest blood pressure reductions in clinical trials. However, in vitro ACE inhibition does not reliably predict in vivo effects because peptides may be degraded during digestion. The blood pressure reductions from food peptides (1-4 mmHg) are much smaller than those from pharmaceutical ACE inhibitors (8-10 mmHg) (Saito, 2008).

Does angiotensin II affect more than just blood pressure?

Yes. Through AT1 receptors, angiotensin II drives cardiac hypertrophy, vascular remodeling, renal fibrosis, and systemic inflammation. The ARB valsartan reduced inflammatory markers TNF-alpha and IL-6 in heart failure patients, demonstrating effects beyond hemodynamics. There is also evidence for central nervous system effects on cognition, mediated by brain-local RAAS signaling (Ho et al., 2018).